THROMBOSIS AND HEMOSTASIS The polyphosphate – factor XII pathway drives coagulation in prostate cancer-associated thrombosis

factor XI. Prostate cancer cells and secreted prostasomes expose long chain polyphosphate on their surface that colocalized with active factor XII and initiated coagulation in a factor XII-dependent manner. Polyphosphate content correlated with the procoagulant activity of prostasomes. Inherited deficiency in factor XI or XII or high-molecular-weight kininogen, but not plasma kallikrein, protected mice from prostasome-induced lethal pulmonary embolism. Targeting polyphosphate or factor XII conferred resistance to pros-tatecancer-driventhrombosisinmice,withoutincreasingbleeding.InhibitionoffactorXII with recombinant 3F7 antibody reduced the increased prostasome-mediated procoagulant activity in patient plasma. The data illustrate a critical role for polyphosphate/factor XII-triggered coagulation in prostate cancer-associated thrombosis with implications for anticoagulation without therapy-associated bleeding in malignancies. ( Blood . 2015;126(11):1379-1389)

[1]  C. Flowers,et al.  Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Evi X. Stavrou,et al.  Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. , 2015, The Journal of allergy and clinical immunology.

[3]  Evi X. Stavrou,et al.  Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. , 2015, Blood.

[4]  G. Raskob,et al.  Factor XI antisense oligonucleotide for prevention of venous thrombosis. , 2014, The New England journal of medicine.

[5]  J. Biedenkapp,et al.  A phase 1 study investigating DX-2930 in healthy subjects. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[6]  T. Renné,et al.  Factor XII Regulates the Pathological Process of Thrombus Formation on Ruptured Plaques , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[7]  B. Monia,et al.  Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. , 2014, Blood.

[8]  T. Renné,et al.  Factor XII inhibition reduces thrombus formation in a primate thrombosis model. , 2014, Blood.

[9]  Michael J. Wilson,et al.  A Factor XIIa Inhibitory Antibody Provides Thromboprotection in Extracorporeal Circulation Without Increasing Bleeding Risk , 2014, Science Translational Medicine.

[10]  G. Ronquist,et al.  Role of exosomes in myocardial remodeling. , 2014, Circulation research.

[11]  V. Tagalakis,et al.  Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants. , 2014, Blood reviews.

[12]  J. Andersen,et al.  Novel Family of Insect Salivary Inhibitors Blocks Contact Pathway Activation by Binding to Polyphosphate, Heparin, and Dextran Sulfate , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[13]  T. Renné,et al.  Time-dependent degradation and tissue factor addition mask the ability of platelet polyphosphates in activating factor XII-mediated coagulation. , 2013, Blood.

[14]  N. Mackman,et al.  Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. , 2013, Blood.

[15]  A. Walker,et al.  Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. , 2013, European journal of cancer.

[16]  Stephanie A. Smith,et al.  Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation. , 2012, Blood.

[17]  B. Sullenger,et al.  Nucleic acid scavengers inhibit thrombosis without increasing bleeding , 2012, Proceedings of the National Academy of Sciences.

[18]  T. Renné,et al.  Platelet‐ and erythrocyte‐derived microparticles trigger thrombin generation via factor XIIa , 2012, Journal of thrombosis and haemostasis : JTH.

[19]  C. Marosi,et al.  Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients , 2012, Journal of thrombosis and haemostasis : JTH.

[20]  J. West,et al.  Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis , 2012, PLoS medicine.

[21]  Stephanie A. Smith,et al.  Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. , 2012, Blood.

[22]  A. Walch,et al.  Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo , 2012, The Journal of experimental medicine.

[23]  G. Ronquist,et al.  Prostasomes are mediators of intercellular communication: from basic research to clinical implications , 2012, Journal of internal medicine.

[24]  P. Reitsma,et al.  The relationship between tissue factor and cancer progression: insights from bench and bedside. , 2012, Blood.

[25]  Meredith C Henderson,et al.  The Genomic and Proteomic Content of Cancer Cell-Derived Exosomes , 2011, Front. Oncol..

[26]  T. Renné,et al.  In vivo roles of factor XII. , 2010, Blood.

[27]  B. Monia,et al.  Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. , 2011, Blood.

[28]  U. Landegren,et al.  Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer , 2011, Proceedings of the National Academy of Sciences.

[29]  S. Cichon,et al.  Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. , 2011, Immunity.

[30]  D. Steinberg,et al.  Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis , 2010, Thrombosis and Haemostasis.

[31]  P. Sonneveld,et al.  Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma , 2010, Thrombosis and Haemostasis.

[32]  J. Freyssinet,et al.  Circulating procoagulant microparticles in cancer patients , 2011, Annals of Hematology.

[33]  James H Morrissey,et al.  Polyphosphate exerts differential effects on blood clotting, depending on polymer size. , 2010, Blood.

[34]  T. Renné,et al.  A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. , 2010, Blood.

[35]  N. Mackman,et al.  Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. , 2010, Thrombosis research.

[36]  Zhongping Cheng,et al.  The interaction of coagulation factor XII and monocyte/macrophages mediating peritoneal metastasis of epithelial ovarian cancer. , 2010, Gynecologic oncology.

[37]  Lijuan Zhang,et al.  Glycosaminoglycans and activated contact system in cancer patient plasmas. , 2010, Progress in molecular biology and translational science.

[38]  T. Renné,et al.  Platelet Polyphosphates Are Proinflammatory and Procoagulant Mediators In Vivo , 2009, Cell.

[39]  J. Blanquer,et al.  Pulmonary tumor embolism as an initial manifestation of pancreatic adenocarcinoma. , 2009, Respiratory care.

[40]  D. Neuberg,et al.  Tumor-Derived Tissue FactorBearing Microparticles Are Associated With Venous Thromboembolic Events in Malignancy , 2009, Clinical Cancer Research.

[41]  D. Lombardo,et al.  Cancer cell–derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo , 2009, The Journal of experimental medicine.

[42]  R. Bertina,et al.  Microparticle‐associated tissue factor activity in cancer patients with and without thrombosis , 2009, Journal of thrombosis and haemostasis : JTH.

[43]  C. Bokemeyer,et al.  Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer , 2009, Thrombosis and Haemostasis.

[44]  A. Gruber,et al.  Factor XI contributes to thrombin generation in the absence of factor XII. , 2008, Blood.

[45]  A. Kakkar.  Venous thromboembolism prophylaxis and treatment in patients with cancer. , 2008, Clinical advances in hematology & oncology : H&O.

[46]  M. Stefanoni,et al.  Coagulation factor levels in non-metastatic colorectal cancer patients. , 2008, The International journal of biological markers.

[47]  James H Morrissey,et al.  Sensitive fluorescence detection of polyphosphate in polyacrylamide gels using 4′,6‐diamidino‐2‐phenylindol , 2007, Electrophoresis.

[48]  N. Mackman,et al.  Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[49]  A. Khorana,et al.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy , 2007, Journal of thrombosis and haemostasis : JTH.

[50]  K. Ekdahl,et al.  Prothrombotic effect of prostasomes of metastatic cell and seminal origin , 2007, The Prostate.

[51]  C. Bokemeyer,et al.  Plasma tissue factor antigen in localized prostate cancer: Distribution, clinical significance and correlation with haemostatic activation markers , 2007, Thrombosis and Haemostasis.

[52]  R. Bertina,et al.  Microparticle‐associated tissue factor activity: a link between cancer and thrombosis? , 2007, Journal of thrombosis and haemostasis : JTH.

[53]  T. Renné,et al.  Platelets promote coagulation factor XII-mediated proteolytic cascade systems in plasma , 2006, Biological chemistry.

[54]  James H Morrissey,et al.  Polyphosphate modulates blood coagulation and fibrinolysis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Masanori Saito,et al.  Direct Labeling of Polyphosphate at the Ultrastructural Level in Saccharomyces cerevisiae by Using the Affinity of the Polyphosphate Binding Domain of Escherichia coli Exopolyphosphatase , 2005, Applied and Environmental Microbiology.

[56]  W. Neugebauer,et al.  Hypotensive effects of hemopressin and bradykinin in rabbits, rats and mice A comparative study , 2005, Peptides.

[57]  T. Renné,et al.  Defective thrombus formation in mice lacking coagulation factor XII , 2005, The Journal of experimental medicine.

[58]  F. Marceau,et al.  International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences , 2005, Pharmacological Reviews.

[59]  M. Hennersdorf,et al.  Disseminated Microvascular Pulmonary Tumor Cell Embolism: A Rare Cause of Fulminant Pulmonary Hypertension , 2004, Oncology Research and Treatment.

[60]  A. Llorente,et al.  Caveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC-3 cell line , 2004, Journal of Cell Science.

[61]  M. Prins,et al.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. , 2003, The New England journal of medicine.

[62]  S. Coughlin,et al.  Protection against thrombosis in mice lacking PAR3. , 2002, Blood.

[63]  J. Hirsh,et al.  A Comparison of the Safety and Efficacy of Oral Antiocoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy , 2000, Thrombosis and Haemostasis.

[64]  M Gent,et al.  Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  M. Wick,et al.  Tumor-related thrombotic pulmonary microangiopathy: review of pathologic findings and pathophysiologic mechanisms. , 2000, Annals of diagnostic pathology.

[66]  L. Melton,et al.  Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. , 2000, Archives of internal medicine.

[67]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[68]  K. Bernstein,et al.  The functional role of angiotensin-converting enzyme as explored by using knockout mice. , 1998, Advances in nephrology from the Necker Hospital.

[69]  J. Quintáns,et al.  Designer and catalytic antibodies. , 1990, The New England journal of medicine.

[70]  A. Aasen,et al.  Studies on components of the contact phase system in patients with advanced gastrointestinal cancer , 1990, Cancer.

[71]  G. Wikander,et al.  Human prostasome membranes exhibit very high cholesterol/phospholipid ratios yielding high molecular ordering. , 1989, Biochimica et biophysica acta.

[72]  H. Dvorak,et al.  Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. , 1983, Cancer research.

[73]  J. Griffin,et al.  Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI. , 1981, Blood.

[74]  J. Caen,et al.  Availability of Platelet Factor 3 and Activation of Factor XII in Thrombasthenia , 1965, Nature.

[75]  A. Trousseau.  Phlegmasia alba dolens. , 1865 .

[76]  Medicale Faites,et al.  Lectures on Clinical Medicine, Delivered at the Hotel-Dieu of Paris , 1838, Edinburgh Medical and Surgical Journal.